On October 5, 2022 Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, reported it will host an in-person and virtual Research & Development event ("The Road Taken") on Saturday, November 12, 2022, from 2:00 p.m. to 5:00 p.m. ET at the Prudential Tower in Boston, MA (Press release, Agenus, OCT 5, 2022, View Source [SID1234621737]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Road Taken will feature both key opinion leaders at the forefront of immunotherapy development for cancer and Agenus’ expanding leadership team. During the event, speakers will highlight recent developments within the Agenus clinical-stage pipeline of novel immunotherapy programs, study details involving botensilimab, a multi-functional Fc-enhanced anti-CTLA-4 which activates innate and adaptive immune responses, opportunities to combine Agenus pipeline assets to overcome immuno-oncology resistance and strategies to reach commercialization as rapidly as possible.
Featured speakers will include:
Michael Atkins, MD, Deputy Director & Professor, Acting Chief, Division of Hematology/Oncology MedStar Georgetown University Hospital; SITC (Free SITC Whitepaper) 2022 Lifetime Achievement Award Recipient
Breelyn Wilky, MD, Director of Sarcoma Medical Oncology, Deputy Associate Director for Clinical Research University of Colorado Medicine; Principal Investigator/Presenter C-800 Study
Steven O’Day, MD, Chief Medical Officer, Agenus
Joseph Grossman, MD, VP and Head of Exploratory Medicines, Agenus
Patricia Carlos, Chief Regulatory, Quality, and Safety Officer, Agenus
The scientific program will take place from 2:00 p.m. to 4:00 p.m. ET and will be followed by a reception from 4:00 p.m. to 5:00 p.m. ET.
The event will be webcast live and institutional investors and research analysts are invited to attend in person. Individuals interested in attending the event in person should contact Agenus Investor Relations at [email protected]. The webcast will be available on the Investors section of the Agenus website at investor.agenusbio.com. To register for the webcast, please click here. Following the webcast, an archived version will be available on the Agenus website.